Treatment of Soft Tissue Expansion in Inactive Thyroid Eye Disease Patients Using Drops of Prostaglandin Analogues
NCT ID: NCT02155049
Last Updated: 2018-02-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
10 participants
INTERVENTIONAL
2014-11-30
2017-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.
NCT01927406
Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study)
NCT02059655
Evaluation of Hyperemia With the Use of Ocular Prostaglandin Analogues
NCT00539526
Bimatoprost as a Treatment for Graves' Orbitopathy
NCT03708627
An Evaluation of Use of Topical Ocular Hypotensive Medication by Compliance
NCT00329095
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Prostaglandin Analogues
The patients will receive a single daily drop of bimatoprost for six months.
bimatoprost 0.03%
The patients will receive a single daily drop of bimatoprost for six months.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
bimatoprost 0.03%
The patients will receive a single daily drop of bimatoprost for six months.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Significant exophthalmos or orbital fat expansion.
Exclusion Criteria
* Known prostaglandin analogues sensitivity.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Rabin Medical Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Maya Eiger
Medical Doctor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Maya Eiger, MD
Role: PRINCIPAL_INVESTIGATOR
Rabin Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ophthalmology clinics, Rabin Medical Center
Petah Tikva, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Thyroid eye disease
Identifier Type: REGISTRY
Identifier Source: secondary_id
TED-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.